Clinical Trial Update: A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Clinical trial update for a Phase 1b study of trastuzumab deruxtecan (T-DXd) combinations in HER2-low advanced or metastatic breast cancer; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING